RxDoctor Payments Data

Sarah Jax, NP

Adult Health · St Louis Park, MNNPI 1164761979

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,181 of the $85,788 with a category attached, or 74.8%. Daiichi Sankyo Inc. accounts for 77.2% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $50,961, more than ten times the $471 reported in 2022. Among adult health clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$85,788in general payments, 2019–2025

Across 168 payments — averaging $510.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$66K
  • AstraZeneca$19K
  • Janssen Scientific Affairs, LLC$430
  • Exelixis Inc.$41
  • E.r. Squibb & Sons, L.L.C.$16
  • Lilly USA, LLC$15

What the payments were for

  • Consulting fees$2,6303%
  • Speaking & faculty fees$64,18175%
  • Travel & lodging$17,99521%
  • Food & beverage$8981%
  • Education$850%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$85,788 in reported general payments places this provider in the 95th percentile of 233 adult health providers in Minnesota.

See all adult health providers in Minnesota

Medicare billing

Part B allowed, 2024
$222,112
Medicare patients
84
Services billed
7,335

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide20$398,436
Lenalidomide16$194,075
Abiraterone Acetate29$3,772
Oxycodone Hcl51$928
Acyclovir42$790
Dexamethasone28$525
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim13$289
Gabapentin19$218
Olanzapine16$176
Famotidine14$165
Ondansetron Hcl15$158
Lorazepam15$82
Prednisone12$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Janssen Scientific Affairs, LLCAbiraterone Acetate$430$3,77229 claims
Lilly USA, LLCOlanzapine$15$17616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 adult health providers in Minnesota.

Other adult health in St Louis Park

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →